2oiq: Difference between revisions

New page: left|200px<br /><applet load="2oiq" size="450" color="white" frame="true" align="right" spinBox="true" caption="2oiq, resolution 2.07Å" /> '''Crystal Structure of...
 
No edit summary
Line 1: Line 1:
[[Image:2oiq.gif|left|200px]]<br /><applet load="2oiq" size="450" color="white" frame="true" align="right" spinBox="true"  
[[Image:2oiq.gif|left|200px]]<br /><applet load="2oiq" size="350" color="white" frame="true" align="right" spinBox="true"  
caption="2oiq, resolution 2.07&Aring;" />
caption="2oiq, resolution 2.07&Aring;" />
'''Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.'''<br />
'''Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.'''<br />


==Overview==
==Overview==
The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and, the PDGF receptor. Imatinib is less effective against c-Src, which is, difficult to understand because residues interacting with imatinib in, crystal structures of Abl and c-Kit are conserved in c-Src. The crystal, structure of the c-Src kinase domain in complex with imatinib closely, resembles that of Abl*imatinib and c-Kit*imatinib, and differs, significantly from the inactive "Src/CDK" conformation of the Src family, kinases. Attempts to increase the affinity of c-Src for imatinib by, swapping residues with the corresponding residues in Abl have not been, successful, suggesting that the thermodynamic penalty for adoption of the, imatinib-binding conformation by c-Src is distributed over a broad region, of the structure. Two mutations that are expected to destabilize the, inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states, is a key to imatinib binding.
The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor. Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src. The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl*imatinib and c-Kit*imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases. Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodynamic penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure. Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.


==About this Structure==
==About this Structure==
2OIQ is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus] with STI and GOL as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2OIQ OCA].  
2OIQ is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus] with <scene name='pdbligand=STI:'>STI</scene> and <scene name='pdbligand=GOL:'>GOL</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2OIQ OCA].  


==Reference==
==Reference==
c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty., Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J, Structure. 2007 Mar;15(3):299-311. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17355866 17355866]
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty., Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J, Structure. 2007 Mar;15(3):299-311. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17355866 17355866]
[[Category: Gallus gallus]]
[[Category: Gallus gallus]]
[[Category: Non-specific protein-tyrosine kinase]]
[[Category: Non-specific protein-tyrosine kinase]]
Line 16: Line 16:
[[Category: Cao, X.]]
[[Category: Cao, X.]]
[[Category: Frank, F.]]
[[Category: Frank, F.]]
[[Category: Henderson, M.N.]]
[[Category: Henderson, M N.]]
[[Category: Kuriyan, J.]]
[[Category: Kuriyan, J.]]
[[Category: Nagar, B.]]
[[Category: Nagar, B.]]
[[Category: Seeliger, M.A.]]
[[Category: Seeliger, M A.]]
[[Category: GOL]]
[[Category: GOL]]
[[Category: STI]]
[[Category: STI]]
Line 27: Line 27:
[[Category: src]]
[[Category: src]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Wed Nov 21 13:12:07 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:19:00 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA